ReviewNature reviews. Cardiology2025
The gut microbiota in thrombosis.
Review in Nature reviews. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Correlation Between Dietary Index for Gut Microbiota With All-Cause and Cardiovascular Mortality in Cardiovascular-Kidney-Metabolic Syndrome Patients.Food science & nutrition · 2026Article
- Elevated serum TMAO levels associate with higher risk of arteriovenous vascular access thrombosis in hemodialysis patients.Clinical kidney journal · 2026Article
- Lachnospiraceae-Derived Extracellular Vesicles Mediate the Cardioprotective Effects of Barley Leaf in Myocardial Infarction by Improving Intestinal Stem Cell Function.Journal of extracellular vesicles · 2026Article
- Effects and mechanism ofWorld journal of gastroenterology · 2026Article
- Soy and the gut microbiome: a bi-directional relationship shaping nutrition and health.European journal of nutrition · 2026Review
- Moderating role of blood inflammatory markers in the vaginal microbiota-fibrinogen relationship in URSA-affected women.Scientific reports · 2026Article
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Acute suppurative cholecystitis complicated by middle hepatic vein thrombosis: a case report.Journal of surgical case reports · 2026Article
- Article
- Bimodal regulation and precision therapy of neutrophil extracellular traps in liver ischemia-reperfusion injury: recent advances.Frontiers in immunology · 2026Review
- Integrated analysis reveals microbiota-metabolite-immune alterations associated with coronary heart disease.Frontiers in microbiology · 2026Article
- Editorial: Interplay of immunothrombosis and thromboinflammation in health and disease.Frontiers in cardiovascular medicine · 2026Article
- Gut microbiota and derived metabolites mediate obstructive sleep apnea induced atherosclerosis.Gut microbes · 2025Article
- Multi-omics integration reveals functional signatures of gut microbiome in atherosclerosis.Gut microbes · 2025Article
- Metabolic reprogramming in ischemic stroke: when glycolytic overdrive meets lipid storm.Cell death & disease · 2025Review
- A Pump-Free, Hydraulic-Amplification Oscillatory Microfluidic Device for Continuous Particle and Cell Manipulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The Critical Role ofReviews in cardiovascular medicine · 2025Review
- Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.Frontiers in microbiology · 2025Article
- The Role of Sterile Inflammation in Thrombosis: Consequences for Cardiovascular Disease and COVID-19.Mediators of inflammation · 2025Review
- The living medicine inside us:Gut microbes reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes and thrombus formation. In addition to impaired gut barrier function promoting low-grade inflammation, gut microbiota-derived metabolites have been shown to act on vascular cell types and promote thrombus formation. Therefore, these meta-organismal pathways that link the metabolic capacities of gut microorganisms with host immune functions have emerged as potential diagnostic markers and novel drug targets. In this Review, we discuss the link between the gut microbiota, its metabolites and thromboembolic diseases.
Indexed as
Identifiers
39289543What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.